Registered Kenya · PPB

GASTORAL TABLETS

AMINOSIDINE SULPHATE

H2021/CTD7561/14726 EACH TABLET CONTAINS: AMINOSIDINE SULPHATE EQUIVALENT TO AMINOSIDINE 250MG NEW/INNOVATOR alimentary tract and metabolism

What it does

Aminosidine is an antibiotic used to treat certain bacterial infections.

Commonly used for: bacterial infections, infections caused by specific bacteria

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.

Source this medicine

Registration & product details

Registration no.
H2021/CTD7561/14726
Registration date
2021-02-09 00:00:00
Expiry date
-
Status
Registered
Active ingredient
AMINOSIDINE SULPHATE
Strength
-
Pack size
PACKED IN ALU-ALU FOIL BLISTERS OF 10 X 10’S AND 2 X 10’S AND CONTAINED IN A UNIT BOX WITH LITERATURE INSERT.
Therapeutic class
NEW/INNOVATOR
ATC class (WHO)
A07AA - Antibiotics
RxNorm RxCUI
7934
Manufacturer / MAH
Laboratory & Allied
Applicant / LTR
LABORATORY & ALLIED LTD
Country of origin
LOCAL
Manufacturer location
National Park East gate road, Lab and, Mombasa Road, Nairobi, Kenya

Source: Pharmacy and Poisons Board · fetched 2026-01-28 20:17:14 · updated 2026-08-03 04:17:42

Disclaimer: This information is sourced from Pharmacy and Poisons Board (Kenya). Always consult a qualified healthcare professional before using any medication.

About this medicine

Aminosidine is an antibiotic used to treat certain bacterial infections.

What it treats

  • bacterial infections
  • infections caused by specific bacteria

How it works

Aminosidine works by stopping the growth of bacteria, helping the body to fight off the infection.

Who it's for

This medication is for patients with infections caused by bacteria that are sensitive to aminosidine.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: aminosidine

BNF-referenced

Aminosidine, also known as paromomycin, is a broad-spectrum aminoglycoside antibiotic derived from the bacterium Streptomyces rimosus var. paromomycinus. It is primarily used to treat infections caused by susceptible strains of bacteria, particularly in cases where other antibiotics are ineffective. Its mechanism involves the inhibition of protein synthesis in bacteria, leading to cell death.

Indications

  • Intestinal amebiasis
  • Bacterial infections caused by susceptible strains

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA. It interacts with the A site of the 30S ribosomal subunit, causing the production of defective polypeptide chains. The accumulation of these defective proteins ultimately results in bacterial death.

Pharmacodynamics

Paromomycin exhibits broad-spectrum antibacterial activity, with its action closely resembling that of neomycin. Its effectiveness is demonstrated both in vitro and in vivo, making it a valuable option for treating specific bacterial infections.

Pharmacokinetics

Aminosidine is poorly absorbed from the gastrointestinal tract when administered orally, which allows it to remain effective in the intestinal lumen. It is primarily excreted unchanged in the urine. Detailed pharmacokinetic data may vary based on the route of administration and patient factors.

Pregnancy

There is limited data on the use of aminosidine in pregnancy. Caution is advised, and it should only be used if the potential benefits outweigh the risks.

Breast-feeding

Aminosidine is excreted in breast milk. Caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

  • Injection

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: aminosidine

PubChem CID 165580

Molecular formula: C23H45N5O14

Mechanism of action

Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA. Bacterial proteins are synthesized by ribosomal RNA complexes which are composed of 2 subunits, a large subunit (50s) and small (30s) subunit, which forms a 70s ribosomal subunit. tRNA binds to the top of this ribosomal structure. Paramomycin binds to the A site, which causes defective polypeptide chains to be produced. Continuous production of defective proteins eventually leads to bacterial death.

Pharmacodynamics

Paromomycin is a broad spectrum aminoglycoside antibiotic produced by <i>Streptomyces rimosus</i> var. paromomycinus. The in vitro and in vivo antibacterial action of paromomycin closely parallels that of neomycin.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.